EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY-NC 4.0

Health Technology Assessment Guidelines and Recommendations Across European Union Countries and the United Kingdom in Rare Disease and Paediatric Populations

Adéla Bártová iD, Jiří Samek, Vera Pinheiro, Barbora Říhová, João Vasco Santos

Applied Health Economics and Health Policy · 2026-03 · 24 (2) · 343-364

DOI: 10.1007/s40258-025-01008-0 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Applied Health Economics and Health Policy, online erschienen am 16.10.2025. Verfasst von Adéla Bártová und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. adela.bartova@med.muni.cz. Hauptthemen laut MEDLINE: Technology Assessment, Biomedical, Rare Diseases, Practice Guidelines as Topic, Guidelines as Topic. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: MSMT, HORIZON EUROPE Coordination and Support Action, Masaryk University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Due to limited clinical data, high uncertainty, and outcome variability, assessing therapies for paediatric and rare disease populations poses specific challenges, often requiring adjustments to standard health technology assessment (HTA) frameworks. This study examines how national HTA guidelines and recommendations across Europe reflect these demands, identifying methodological adaptations and country-specific disparities. METHODS: HTA organisations across the 27 EU Member States and the UK were identified via INAHTA, EUnetHTA, and ISPOR reference listings. Publicly available documents were screened, and 29 relevant national guidelines were selected. A structured document analysis was performed using a predefined coding framework. Key terms were systematically searched, and content was categorised into thematic domains. RESULTS: Among the 29 guidelines, 16 included references to rare disease populations, and 12 to paediatric populations. For paediatric populations, most references focused on quality-of-life measurement and proxy assessments. Adaptations for rare diseases recognised flexible cost-effectiveness thresholds (e.g. adjusted incremental cost-effectiveness ratios [ICERs] or gross domestic product [GDP]-based modifiers), tailored economic modelling, and acceptance of alternative data sources. However, significant variability was observed across countries, with no consistent pattern. CONCLUSION: While several HTA bodies have introduced adjustments for paediatric and rare disease populations, guidance often remains limited and heterogeneous. The findings indicate that HTA guidelines and recommendations require further collaboration to properly define and account for the specific needs of these patients. Methodological shortcomings are mainly due to the nature of these diseases, where the limited data available are primarily from clinical practice and often lack comparative effectiveness evidence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Technology Assessment, BiomedicalRare DiseasesPractice Guidelines as TopicGuidelines as TopicPediatricsHumansUnited KingdomChildEuropean UnionCost-Benefit AnalysisEurope

Autor:innen und Institutionen

  • Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. adela.bartova@med.muni.cz.
  • Centre of Excellence CREATIC, Faculty of Medicine, Masaryk University, Brno, Czech Republic. adela.bartova@med.muni.cz.
  • Centre of Excellence CREATIC, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • Public Health Unit, ULS Matosinhos, Matosinhos, Portugal.
  • Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, RISE-Health, University of Porto, Porto, Portugal.
  • Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. brihova@med.muni.cz.

ORCID-Profile: Adéla Bártová

Förderung

  • MSMT
  • HORIZON EUROPE Coordination and Support Action
  • Masaryk University

Zitieren

APA

Bártová, A., Samek, J., Pinheiro, V., Říhová, B., & Santos, J. V. (2026). Health Technology Assessment Guidelines and Recommendations Across European Union Countries and the United Kingdom in Rare Disease and Paediatric Populations. Applied Health Economics and Health Policy, 24(2), 343-364. https://doi.org/10.1007/s40258-025-01008-0

Vancouver

Bártová A, Samek J, Pinheiro V, Říhová B, Santos JV. Health Technology Assessment Guidelines and Recommendations Across European Union Countries and the United Kingdom in Rare Disease and Paediatric Populations. Applied Health Economics and Health Policy. 2026;24(2):343-364. doi:10.1007/s40258-025-01008-0

BibTeX
@article{Brtov2026,
  author = {Bártová, Adéla and Samek, Jiří and Pinheiro, Vera and Říhová, Barbora and Santos, João Vasco},
  title = {Health Technology Assessment Guidelines and Recommendations Across European Union Countries and the United Kingdom in Rare Disease and Paediatric Populations},
  journal = {Applied Health Economics and Health Policy},
  year = {2026},
  volume = {24},
  number = {2},
  pages = {343--364},
  doi = {10.1007/s40258-025-01008-0}
}
Kostenlos starten →